• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Journal PharmaceuticalIntelligence.com
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2022 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • SOP Web STAT
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

Ofer Markman, PhD – Advisor to LPBI Group’s Founder on the Biotech Ecosystem in Israel and Domain Expert on Text Analysis with ML

INACTIVE – 12/31/2022

Ofer Markman, PhD

oferm2015@gmail.com

+972-523-275720

Haifa, Israel

UPDATED on 11/9/2020

Selected Projects

Israel – 1Q 2021

1. Will recruit and instruct a student on review and prioritization ranking of Aviva’s LinkedIn 1st degree connections in ISRAEL – find appropriate intern

2.  Intern under my guidance will send contact N=30 fromOfer’s 1500 Contacts in Israel a note on LinkedIn about 2.0 LPBI exploring Expansion in Israel

3.  Communicate The Opportunities for M&A, JV and Partnership

4.  as part of the internship Instruct and guide an intern/student in preparation and management of a followup table or mini-CRM

5.  On March 31, 2021 End of 1Q 2021 of 2.0 LPBI Life – Report to management outcome for 2.0 LPBI and ISRAEL

Europe – 2Q 2021

with a Europe intern

1.  Will contact N=30  on LinkedIn about  2.0 LPBI exploring Expansion in Europe in Country 1,2,3,4,5

2.  Communicate The Opportunities for M&A, JV and Partnership to 6 Contacts as in 3.1.1, above

3.  develop a CRM tool or management and followup tool as a table

4.  On June 3o, 2021 End of 2Q 2021 of 2.0 LPBI Life – Report present to management outcomes of f 2.0 LPBI and Europe

 

BIO

Dr. Markman is a serial entrepreneur with over 20 years of experience serving as CEO or CXO for several companies in the biotechnology, technology, and food technology space. He has raised over $70M in venture capital financing for companies that have had various successful exits, including some companies that remain private and others that have had an IPO. Most notably he was a founding partner of Procognia that has raised over $50M in 2007.

Dr Markman was a lecturer of Glycotechnology at the Ort Braude Engineering College  and is leading a Science internship program reaching its 80 interns in 3 years land-mark goal

Ofer Published articles and invented multiple patents, Products he has led to markets were sold at over 8 digit dollars of revenue worldwide. As a leader in acceleration plans Dr Markman assisted dozens of entrepreneurs and young companies reach their business goals.

Dr. Markman holds a PhD in Chemistry from Boston College, and worked with Nobel Laureate Ada Yonath for his Master’s Degree.

  • Published 10 journal articles
  • Inventor in 14 granted patents
  • Major (res.) in Military Intelligence and HLS
  • 2x Entrepreneur, raised $30M for two companies founded.

Curriculum Vitae

Science: AI in healthcare, AI in medical diagnosis, BioIT Bioinformatics, Biomarkers and medical diagnostics, Glycobiology, Cancer and current Therapeutics, Microbiome, Clinical diagnostics, Diagnostic immunology

Business:

  1. Biotech venture creation
  2. Joint Venture 2.0 LPBI Group (30%) with ABI-Lab (70%)

Business Development responsibilities @LPBI: Biotech in Israel, in Switzerland and in other countries in Europe

Plan for Business Development Activity at 1.0 LPBI 4Q 2020

  • TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

    Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health

    • Text Analysis done in parallel on three LPBI’s Article Collections building a Proof of Concept performed byLPBI Group’s 2020/2021 Academic Internship in Medical Text Analysis (MTA) with Natural Language Processing (MTA-NLP): 9/2020 – 9/2021 – Academic INTERNSHIPS in LIFE SCIENCES, Medicine, Biological Sciences, Drug Discovery 
    • Inputs for Proof of Concept are the following three:

    (1) Top 12 articles by views (all domains)

    (2) Sixteen Cancer Articles representing 8 topics in Cancer Volume 1

    (3) Sixteen Genomics Articles representing 21 chapters in Genomics Volume 1

SEE TNS #1: Phase 2 and Phase 3 in  https://pharmaceuticalintelligence.com/vision/

Roles on 2.0 LPBI Group’s TNS #1,2,3,4,5,6 https://pharmaceuticalintelligence.com/vision/

TNS #1: See above

TNS #2: EXEMPT due to conflict of interests

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio  [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Dr. Nir for Drug Discovery

TNS #6:  e-Books Translations into Japanese, Spanish, Russian 

Plan for Business Development Activity at 2.0 LPBI 1Q 2021

  • PENDING

 

Publications with Leaders in Pharmaceutical Business Intelligence (LPBI) Group

WordCloud Visualization of LPBI’s Top Twelve Articles by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

Curators: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD, Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/07/21/wordcloud-visualization-of-lpbis-top-twelve-articles-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

 

WordCloud Visualization of LPBI’s Top Sixteen Articles on CANCER in eight categories and by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

Curator: Stephen J. Williams, PhD and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2020/07/30/wordcloud-visualization-of-lpbis-top-sixteen-articles-on-cancer-in-eight-categories-and-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

 

WordCloud Visualization of LPBI’s Top Sixteen Articles on GENOMICS by Views at All Time and their Research Categories in the Ontology of PharmaceuticalIntelligence.com

Curators: Stephen J. Williams, Aviva Lev-Ari, PhD, RN and WordCloud Producers: Daniel Menzin, Noam Steiner-Tomer, Zach Day, Ofer Markman, PhD

https://pharmaceuticalintelligence.com/2020/07/30/wordcloud-visualization-of-lpbis-top-sixteen-articles-on-genomics-by-views-at-all-time-and-their-research-categories-in-the-ontology-of-pharmaceuticalintelligence-com/

SID ISRAEL Panel 31 March 2020 Covid 19 outbreak in the Developing world

LIVE Coverage & Reporter’s Perspective: Ofer Markman, PhD

https://pharmaceuticalintelligence.com/2020/04/12/sid-israel-panel-31-march-2020-covid-19-outbreak-in-the-developing-world/

An expert opinion by Dr. Ofer Markman – A sweet perspective on the COVID-19 pandemic – glycobiologist view on the effort to curb the pandemic.

https://pharmaceuticalintelligence.com/2020/08/16/a-sweet-perspective-on-the-covid-19-pandemic-glycobiologist-view-on-the-effort-to-curb-the-pandemic/

The Relevance of Glycans in the Viral Pathology of COVID-19

Reporter: Ofer Markman, PhD

https://pharmaceuticalintelligence.com/2020/03/23/glycans-in-the-viral-pathology-of-covid-19/

Clustering of Country-Based Data in COVID-19 Infections by Coronavirus outbreak features ­ First wave, Data up to date 28/5/2020 | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Authors: Ofer Markman, PhD, Doha Akad, Jared Lefkov

Clustering of Country-Based Data in COVID-19 Infections by Coronavirus outbreak features – First wave, Data up to date 28/5/2020

Opportunity Mapping of the E-Health Sector prior to COVID19 Outbreak | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Authors: Ofer Markman, PhD, Doha Akad, Jared Lefkov

Opportunity Mapping of the E-Health Sector prior to COVID19 Outbreak

 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to print (Opens in new window)
  • Click to email a link to a friend (Opens in new window)

Like this:

Like Loading...

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 9,459 other subscribers
  • Recent Posts

    • Creating a Twitter Space for @pharma_BI for Live Broadcasts March 14, 2023
    • The Vibrant Philly Biotech Scene: Recent Happenings & Deals March 11, 2023
    • Peak oxygen uptake (VO2peak) quantified fitness: Lifelong and late-onset athletes had higher VO2peak than non-athletes March 7, 2023
    • Merck’s sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6, 2023
    • Bacterial multidrug resistance problem solved by a broad-spectrum synthetic antibiotic March 1, 2023
    • Genetic variation causes human lupus, systemic lupus erythematosus (SLE) February 23, 2023
    • Mimicking vaginal cells and microbiome interactions on chip microfluidic culture February 14, 2023
    • Press Release for Five Bilingual BioMed e-Series in English and in Spanish January 29, 2023
    • 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
    • Verily announced other organizational changes, 1/13/2023 January 16, 2023
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 Amandeep Kaur
    • 1 Aashir Awan, Phd
    • 1 Abhisar Anand
    • 1 Adina Hazan
    • 1 Alan F. Kaul, PharmD., MS, MBA, FCCP
    • 1 alexcrystal6
    • 1 anamikasarkar
    • 1 apreconasia
    • 1 aviralvatsa
    • 1 David Orchard-Webb, PhD
    • 1 danutdaagmailcom
    • 1 Demet Sag, Ph.D., CRA, GCP
    • 1 Dror Nir
    • 1 dsmolyar
    • 1 Ethan Coomber
    • 1 evelinacohn
    • 1 Gail S Thornton
    • 1 Irina Robu
    • 1 jayzmit48
    • 1 jdpmd
    • 1 jshertok
    • 1 kellyperlman
    • 1 Ed Kislauskis
    • 1 larryhbern
    • 1 Madison Davis
    • 1 marzankhan
    • 1 megbaker58
    • 1 ofermar2020
    • 1 Dr. Pati
    • 1 pkandala
    • 1 ritusaxena
    • 1 Rick Mandahl
    • 1 sjwilliamspa
    • 1 Srinivas Sriram
    • 1 stuartlpbi
    • 1 Dr. Sudipta Saha
    • 1 tildabarliya
    • 1 vaishnavee24
    • 1 zraviv06
    • 1 zs22

Powered by WordPress.com.

WPThemes.


 

Loading Comments...
 

    %d bloggers like this: